EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients

Autor(es)

Honma, Helen N. ^[1] ; Perroud, Jr., Mauricio W. ^[1] ; Leme, Mauricio S. T. ^[1] ; Barbeiro, Aristoteles S. ^[1] ; Saad, Bruna A. ^[2] ; Morcillo, Andre M. ^[3] ; Vassallo, Jose ^[4] ; Costa, Daniel B. ^[5] ; Zambon, Lair ^[1]

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Sch Med Sci, Dept Internal Med, Campinas, SP - Brazil

^[2] Ctr Univ Lusiada, Sch Med, Sao Paulo - Brazil

^[3] Univ Estadual Campinas, Dept Pediat, Campinas, SP - Brazil

^[4] Univ Estadual Campinas, Sch Med Sci, Dept Anat Pathol, Campinas, SP - Brazil

^[5] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol, Boston, MA 02215 - USA

• Tipo de documento: Artigo Científico
• Fonte: TARGETED ONCOLOGY; v. 9, n. 4, p. 389-394, DEC 2014.
• Citações Web of Science: 2

Resumo

The aim of the study was to analyze the frequency of epidermal growth factor receptor (EGFR) mutations in Brazilian non-small cell lung cancer patients and to correlate these mutations with response to benefit of platinum-based chemotherapy in non-small cell lung cancer (NSCLC). Our cohort consisted of prospective patients with NSCLCs who received chemotherapy (platinum derivates plus paclitaxel) at the {[}UNICAMP], Brazil. EGFR exons 18-21 were analyzed in tumor-derived DNA. Fifty patients were included in the study (25 with adenocarcinoma). EGFR mutations were identified in 6/50 (12 %) NSCLCs and in 6/25 (24 %) adenocarcinomas; representing the frequency of EGFR mutations in a mostly self-reported White (82.0 %) southeastern Brazilian population of NSCLCs. Patients with NSCLCs harboring EGFR exon 19 deletions or the exon 21 L858R mutation were found to have a higher chance of response to platinum-paclitaxel (OR 9.67 {[}95 % CI 1.03-90.41], p=0.047). We report the frequency of EGFR activating mutations in a typical southeastern Brazilian population with NSCLC, which are similar to that of other countries with Western European ethnicity. EGFR mutations seem to be predictive of a response to platinum-paclitaxel, and additional studies are needed to confirm or refute this relationship. (AU)

• Processo FAPESP: 09/52574-5 - Correlação da resposta a quimioterapia e sobrevida em pacientes com câncer de pulmão não pequenas células baseado em biomarcadores pelas análises genotípicas e expressão protéica
• Beneficiário: Lair Zambon
• Modalidade de apoio: Auxílio à Pesquisa - Regular